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Abstract
Background: Multiple Sclerosis has a great impact on psychological functioning of patients and can be associated
with various mental health disorders and symptoms. The most prevalent one is depression, which ranges from 15
to 47 %.
Mindfulness Based Interventions are a relatively brief and cost-effective program that has been studied in patients
with several chronic diseases and recently also in patients with Multiple Sclerosis. Mindfulness Based Interventions
are based on the assumption that a non-judgmental awareness and acceptance of one’s moment-to-moment
experience can have a positive effect on the adaptation to the disease, reducing the psychological burden and
improving patients’ quality of life.
Several studies concluded that Mindfulness Based Interventions can be beneficial in terms of improving both
psychological and psychical aspects of Multiple Sclerosis, but none of them compared the intervention with an
active control group. The primary objective of the study is to evaluate the efficacy of a group-based Mindfulness
Based Intervention on depressive symptoms in patients with Multiple Sclerosis, as compared with an active control
group.
Methods: The study design is a randomized controlled clinical trial. Eighty-eight patients with Multiple Sclerosis
and depressive symptoms will be recruited and randomized to either Mindfulness Based Intervention or an active
control group. The latter is designed to control for non-specific elements of the intervention and it comprises
psycho-education and relaxation techniques. The primary outcome is the reduction of depressive symptoms as
measured via the Beck Depressive Inventory-II. Secondary outcome measures are level of quality of life, anxiety,
perceived stress, illness perception, fatigue and quality of interpersonal relationship. Outcomes will be assessed at
baseline, after treatment and 6 months after the end of the treatment. Caregivers will participate in groups
together with patients.
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Discussion: As far as we know this trial will be the first randomized controlled trial testing the efficacy of group-
based Mindfulness Based Intervention for patients with Multiple Sclerosis with a comparison with an active control
group with a specific focus on depressive symptoms.
Trial registration: NCT02611401.
Keywords: Multiple Sclerosis, Depression, Quality of Life, Mindfulness, Mindfulness Based Intervention, Psycho-
education, Relaxation, Caregiver
Background
Multiple Sclerosis (MS) is a chronic demyelinating dis-
ease with an onset typically during young age, that poses
a significant emotional burden with heavy psychosocial
consequences. People with MS have to deal with the un-
predictability of the disease, the loss of function and dis-
ability, a series of debilitating and changeable symptoms
and the uncertain perspectives of the disease. The phys-
ical limitations of the disease have also a great impact on
social functioning.
Previous studies have focused on the psychosocial im-
pact of MS, showing a high prevalence of depression, anx-
iety and a reduced Quality of Life (QoL) [1–6]. Depression
affects from 15 to 47 % of patients [7, 8], with lifetime
prevalence estimates at 50 % [9]. This prevalence is much
higher than in other chronic neurological diseases [1] and
is three times higher than in the general population [4].
There is a strong correlation between fatigue and de-
pression [10] and also between depression and anxiety
[11], and these interactions have important implications
for QoL [1].
The Goldman Consensus Conference Study Group on
depression in MS stated that affective disorders are not
usually recognized by clinicians, and do not routinely
receive treatment [12]. More recently, the American
Academy of Neurology [13] formulated evidence-based
recommendations for screening, diagnosing and treating
psychiatric disorders in individuals with MS and recom-
mended future research on the effectiveness of treat-
ments frequently used in the non-MS population.
Furthermore, a recent study on psychological treat-
ment of depressive symptoms in patients with medical
disorders stated that treating comorbid depression
should be one of the priorities in medical care settings
[14]. Feinstein [4, 15] highlighted that treatments for de-
pression in public health care services may also be ad-
justed according to the availability of resources and
access to them. Thereby it is essential to establish brief
and cost-effective interventions to reduce depression
symptoms and the psychological burden and to improve
QoL of MS patients [15].
To our knowledge, so far there are only few studies
with an adequate methodology that investigated the effi-
cacy of psychopharmacologic treatment for depression
in MS. A Cochrane Review [16] showed that Serotonin
Selective Reuptake Inhibitors are quite effective, but with
prominent side effects and high drop-out rates. Several
studies of psychological interventions have shown bene-
fits upon depression and QoL of life in patients with
MS. A Cochrane review [17] and a recent meta-analysis
[18] identified that Cognitive Behavioural Therapy (CBT)
had a moderate effect on depression.
Recently, group intervention programs have been pro-
posed to improve the well-being and health status of pa-
tients with chronic illnesses, with the aim of reducing
distress and social isolation related to the disease by
means of a group sharing support. In particular, Mind-
fulness Based Interventions (MBIs) are a relatively brief
and cost-effective program that has been employed ef-
fectively in patients with several diseases, such as
chronic pain, cancer, fibromyalgia [19] and also recently
in patients with MS [20, 21].
MBIs are based on the premise that an attitude of non-
judgmental awareness and acceptance of the present mo-
ment have an effect on the distressing tendencies to escape
from or to over-engage with one’s disturbing feelings, emo-
tions and thoughts. Mindfulness can positively have an ef-
fect on coping strategies and on the adaptation to the
disease, by encouraging patients to relate differently to
their physical and psychological symptoms [4].
Several neuroimaging studies and of biological markers
[22–24] had also pointed out the effects of mindfulness at
a neurobiological level, showing its effects on the regula-
tion of emotional responses through the inhibition of
amygdala by a proper functioning of the prefrontal cortex.
MBIs efficacy was also associated with an altered cortisol
and immune patterns consistent with less stress and mood
disturbance, and decreased blood pressure.
In recent years, several studies provided support for the
positive association of mindfulness with both emotion
regulation and QoL in MS patients. Senders et al. [25]
found that trait mindfulness is significantly associated with
decreased psychological stress, a more constructive coping
profile, increased resilience and better QoL in MS. The
study of Schirda et al. [26] corroborated these results,
highlighting that reduced emotion dysregulation may be a
critical pathway linking mindfulness and QoL in MS, es-
pecially in those with higher symptoms of depression.
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Recently two systematic reviews [20, 21] focused on the
efficacy of MBIs in MS patients, concluding that MBIs can
be beneficial, especially in terms of improving the QoL,
mental health parameters (such as anxiety and depression)
and physical parameters (as fatigue). Similar results were
recently obtained also in a pilot randomized controlled
trial in patients with Progressive MS [27]. Furthermore,
MBIs were shown to have a broad feasibility and satisfac-
tion, a low attrition rate and no side effects [20, 28].
The major limit pointed out by all these studies is the
absence of a comparison of MBI intervention with an ac-
tive control group. Both reviews claimed for additional
rigorous clinical trials with larger sample size and with ro-
bust methodological techniques [20, 21].
In order to overcome this limit, in our randomized con-
trolled trial we will include an active control intervention.
Moreover, we aim to evaluate the efficacy of the MBI in
MS patients who have depressive symptoms. In fact, NICE
guidelines [29] indicated that psychological interventions
such as mindfulness or psycho-education, combined with
drug therapies or alternative to them depending on the
case, resulted more effective both in terms of efficacy and
in term of cost-effectiveness compared to drug therapy
alone. As highlighted by previous study [19, 26], MBIs
may be more effective and useful in populations with
mood disorders. Furthermore, our project aims to involve
patients’ caregivers asking them to participate in the group
the patient has been assigned to. We expect that care-
givers will benefit from the treatment received, due to the
load of stress and difficulties related to the management
of a chronic disabling diseases like MS.
The aim of the current paper is to describe our re-
search design. Our primary objective is to evaluate the
efficacy of MBI on depressive symptoms of MS patients,
compared to an active control intervention, and to as-
sess whether these expected benefits can be maintained
at the 6-month follow-up. Secondary aims of the study
are: to assess whether after the Mindfulness Based Inter-
vention there is an improvement in QoL, anxiety, fatigue
and perceived stress levels; to evaluate the efficacy of the
intervention on the perception of the illness and
whether participating in MBI also improve interpersonal
relationships; to evaluate the efficacy of MBI on depres-
sion, QoL and related symptoms in caregivers.
We hypothesize that MBI intervention will lead to a
reduction of depressive symptoms, and its associated
symptoms both at a physical and psychological levels,
compared to an active control group.
Methods
Design
This study is a randomized controlled clinical trial.
The study is registered in ClinicalTrials.gov registry
as NCT02611401.
Setting
Participants will be enrolled at the CReSM Unit (Re-
gional Reference Centre for Multiple Sclerosis), affiliated
with the San Luigi University Hospital of Orbassano,
Italy, which includes about 1500 patients with MS.
The study protocol is approved by the Medical Ethics
Committee of San Luigi Gonzaga University Hospital.
Participants
The subjects of the study will be 88 patients with MS
and depressive symptoms that will be pre-screened from
a catchment group of about 600 patients using the Beck
Depression Inventory-II (BDI-II). Those who have a
score on BDI-II greater than 13 (considered the best ap-
proach to screening for depression in MS patients fol-
lowing the Goldman Consensus Group) [12] will be
assessed with the other psychological measures.
Inclusion criteria are as follows:—definite diagnosis of
MS (Mc Donald Criteria) [30] evaluated by a neurologist of
the CReSM Unit at least 6 months prior the beginning of
the study;—relapsing-remitting and secondary progressive
disease;—age of 18–65 years;—clinically inactive phase of
the disease;—an Expanded Disability Status Scale (EDSS)
score lower than 6.5;—fluent Italian speaker;—legal cap-
acity to consent to the treatment;—willingness to abstain
from or to suspend all concomitant psychological treat-
ment;—suspension of all psychotropic medications at least
1 month before the treatment or maintenance at baseline
level throughout the study.
Exclusion criteria are as follows:—current severe Major
Depressive Disorder (as assessed by Structured Clinical
Interview-DSM-IV (SCID);—severe suicidality, including
ideation, plan, and intent;—current serious psychological
and psychiatric disorders, including psychotic disorders,
bipolar disorders, active substance abuse (as assessed by
the SCID);—presence of overt dementia;—corticosteroid
treatment during the previous 30 days;—other serious
medical disorders in addition to MS;—current pregnancy.
The research protocol will be proposed to patients
who will meet the inclusion criteria, with an explanation
of the aims of the study and declaring the possibility that
they are assigned by random allocation to MBI group or
to control group. Patients who will give informed con-
sent will be included in the study.
Randomization and blinding
Patients will be randomly allocated to one of the two
conditions: MBI and active control group. Patients will
be randomized to the intervention or control group with
a 1:1 ratio, using a block-wise randomization sequence
(block size of 4 and 6).
The sequence will be determined by an independent re-
searcher, blind to initial assessment to ensure allocation
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concealment, using a random number generator
(www.randomizer.org).
Treatment assignment will be communicated to the
patients by the study coordinator to ensure the blinding
of the evaluators.
One family member or caregiver for each patient is
asked to join the group the patient has been assigned to.
Because it is not possible to stratify for this variable, and
as it is not our primary outcome, we expect that due to
randomization the proportion of caregivers participating
in the study will be distributed randomly and equally in
both groups.
Assessments
All patients in the care of the CReSM are evaluated
by neurologists with the EDSS (Expanded Disability
Status Scale). The psychological assessment will be
performed with the same timing and tools: at baseline
(T0), after treatment (T1) and 6 months after the end
of the group intervention (T2). The psychological as-
sessment of the patients entering the study will be
performed by trained Clinical Psychologists with more
than 3 years of clinical practice in the liaison setting.
The psychological assessment will be independent and
blind to treatment, and will encompass the adminis-
tration of the following clinical interview and self-
report questionnaires.
 Structured Clinical Interview-DSM-IV (SCID-IV)
[31]: is a well-validated, semi-structured interview,
which covers the Diagnostic and Statistical Manual
of Mental Disorders, 4th Edition (DSM-IV) criteria
for adult psychopathology.
 Beck Depression Inventory-II (BDI) [32]: it is a 21-
item self-report instrument that assesses the pres-
ence and severity of symptoms consistent with the
criteria of the DSM-IV. Each item is scored on a 4
point scale ranging from 0 to 3 with total scores ran-
ging from 0 to 63, where higher scores are indicative
of higher levels of depression. The Consensus Group
for depression in MS [12] and the American Acad-
emy of Neurology [13] stated that the best approach
to screening for depression in general MS popula-
tions is to use the BDI-II, with a cut-off score of 13.
 Functional Assessment of Multiple Sclerosis (FAMS)
[33]: it is a self-report scale designed to assess six
primary aspects of QOL of patients with MS: Mobil-
ity, Symptoms, Emotional Well-Being, General Con-
tentment Thinking and Fatigue, and Family/Social
Well-Being.
 Beck Anxiety Inventory (BAI) [34]: is a 21-item self-
report measure that assesses cognitive, somatic, and
affective anxiety symptom severity. Each item is
rated on a Likert scale from 0 to 3, and the total
BAI score can range from 0 to 63, where higher
scores are indicative of higher levels of anxiety.
 Fatigue Severity Scale (FSS) [35]: is a self-
administered questionnaire with 9 items investigat-
ing the severity of fatigue in different situations dur-
ing the past week. This items are designed to
differentiate fatigue from clinical depression.
 Inventory of Interpersonal Problems (IIP) [36]: is a
self-report instrument that identifies a person’s most
salient interpersonal difficulties. The IIP contains 64
statements describing common interpersonal
problems.
 Brief Illness Perception Questionnaire (IPQ-Brief )
[37]. It is a nine item self-report measure that is
used to assess the major components of illness per-
ceptions. The questionnaire assesses each dimension
using a single-item scale from 0 to 10.
 Perceived Stress Scale (PSS) [38]. It is a 10-item
measure of the degree to which situations in one’s
life are appraised as stressful. The items refer to peo-
ple’s subjective appraisals of events.
 Post Traumatic Growth Inventory (PTGI) [39], a
21-item instrument for assessing positive outcomes
in people who have experienced traumatic events. It
measures five domains or factors: relating to others,
new possibilities, personal strength, spiritual change,
and a deeper appreciation of life.
 Five Facet Mindfulness Questionnaire (FFMQ) [40], a
39-item self-report questionnaire measuring five
unique facets associated with the overarching con-
struct of mindfulness disposition. The facets included
are observing, describing, acting with awareness, non-
judgment, and nonreactivity.
 A clinical diary of the homework practice: it is a
clinical diary regarding frequency and duration of
homework assigned in the group sessions, that
patients are asked to fill out every time they spent
time on homework practice.
Caregivers will be asked to complete the same self-report
measures administered to the patients, except for the FSS
and the IPQ-Brief, which are related to the disease. Instead
of FAMS, caregivers will complete the WHO-Quality of
Life Brief [41].
Intervention
Treatments will be independent and blinded from the
clinical psychologists conducting the clinical assess-
ments. The experimental group will undergo a 8
weekly sessions of 3 h each with a group based
Mindfulness Based Intervention. The control group
will follow the same structure as the Mindfulness
Based Intervention.
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Mindfulness based intervention (MBI)
The MBI is based on Mindfulness Based Stress
Reduction (MBSR) [42] and Mindfulness Based Cog-
nitive Therapy (MBCT [43] protocols. The MBI com-
prises an 8-week group program. Participants will
took part in a 3 h single weekly sessions, and there
will be also an additional all-day session of 7 h. Each
session will cover specific exercises and topics within
the context of mindfulness practice and training
(body scan, breath meditation, walking meditation,
yoga exercises). Participants will be required to carry
out daily 45-min homework assignments, which con-
sist on mindfulness exercises and mindfulness applica-
tions in everyday life. We will attempt to objectively
verify the execution of homework practice through
the clinical diary.
In order to maximize the clinical utility in people with
MS suffering from depressive symptoms, we will tailor
mindfulness intervention on the needs of this specific
population [44].
We will apply a modified MBSR protocol integrated
with techniques from Sensorimotor Psychotherapy (SP)
[45], in which:
– particular emphasis will be paid to somatic
resources (grounding, centering, boundaries,
lengthening the spine, body self-soothing techniques,
etc.) to stabilize the emotional state to prepare and
sustain the mindful disposition;
– explanation of stress response will be integrated with
the concept of “window of tolerance” [46], that is
the range of optimal arousal which is necessary to
stay in touch with the present moment experience.
This concept allows a more precise awareness of the
arousal state, recognizing hyper-arousal and hypo-
arousal symptoms, and consequently to manage
them more effectively;
– considering the attention deficits, which may be due
both to neuropsychological deficits and to the
depression itself, great attention is paid to attention
training;
– considering interpersonal deficits in depression,
interpersonal mindful listening is specifically
addressed, developing the capacity to listen in a
mindful state, creating a space inside to observe in a
compassionate and non-judgmental way sensations,
emotions and thoughts evoked by the other’s
narration;
– great treatment emphasis will be paid on acceptance
and self-compassion, and specific tools are used to
increase it, such assessment and decentering of
negative cognitions, and mindful body self- touch,
becoming aware of sensations, feelings, thoughts and
needs in the intimate relationship with the self.
MBI groups will be delivered by a psychotherapist with
mindfulness training experience, who is experienced in
working with people with MS.
Active control group
Our control group is based on the active control group
of the study of Grossman et al. [47].
This intervention was designed to control for the non-
specific elements of the MBI treatment. It will be based
on a psycho-educational framework and will include
some relaxation techniques.
In each session is discussed a MS-related topic. Relax-
ation and gentle stretching exercises will be proposed at
the end of each session. Homework and the material
(photocopies, slides, etc.) discussed in group sessions is
left to each participant to encourage participants to
practice exercises between sessions. This intervention
will follow the same structure and weekly format of the
MBI intervention. The only difference will be the ab-
sence of an all-day session. Each component has its
counterpart in the MBI curriculum, but emphasis is
placed upon not describing or training mindfulness skills
to the control group. The groups will be delivered by a
psychotherapist with relaxation training experience, who
is experienced in working with people with MS.
Outcome measures and statistical analysis
Primary outcome measures will be: 1) the improvements
of BDI-II score from T0 to T2; 2) the proportion of par-
ticipants at T2 that do not have a BDI-II score greater
than 13.
Secondary outcome measures will be the comparison
of the scores of FAMS, BAI, FSS, IIP, IPQ-Brief, PSS,
PTGI and FFMQ of the two groups at T0, T1 and T2.
Another secondary outcome aim will be the reduction of
psychological symptoms (BDI-II, BAI, IIP, PSS, PTGI)
and a reduction in QoL (WHOQoL-Brief ) in caregivers
of patients with MS.
The efficacy of MBI will be evaluated by comparing
the results to different instruments administered to pa-
tients before participating at MBI (T0), after MBI (T1)
and at the 6-month follow-up (T2) and by comparing
these results with those of patients who were included in
the active control group. Intention to treat analyses will
be used.
A longitudinal (within subjects) and cross sectional
(between subjects) evaluation of our outcome measures
will be performed through a repeated measures multi-
variate analysis of covariance (ANCOVA) using the SPSS
GLM procedure. The pre-treatment value will be the co-
variate, and the treatment condition will be the inter-
subjects factor. The intra-subject factor will be a time
condition, relating to changes from post-treatment to 6-
month follow-up.
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The proportion of participants at T1 and T2 no longer
meeting the BDI-II cut-off criteria for depression will be
evaluated through the Chi square test.
Power calculation
The sample size calculation is based on the primary out-
comes for patients with MS.
Statistical power calculation was based on previous
studies [28, 48]: assuming power =0.80 and 0.05 signifi-
cance, a minimal sample size of 44 patients/group will
be required, based on an effect size of 0.54.
To obtain the 88 patients needed for the study, it is
expected to do the screening of at least 600 patients. On
the basis of the information that is available on the
prevalence of depression in MS patients, on the average
25 % in previous studies, this number should guarantee
there will be at least 150 participants. The number of re-
fusals and treatment interruptions is estimated at not
above 40 % which leads to about 90 cases.
Discussion
As far as we know this trial will be the first randomized
controlled trial testing the efficacy of group-based MBI for
patients with MS with a comparison with an active control
group with a specific focus on depressive symptoms.
Secondary outcome measures are levels of QoL, anx-
iety, perceived stress quality of interpersonal relation-
ship, illness perception and fatigue.
The main strengths of this trial are: 1) a comparison
with an active control group; 2) a main focus on depres-
sive symptoms; 3) psychological symptoms are not only
self-reported but our assessment includes also a clinical
interview; 4) involvement and assessment of caregivers’
psychosocial functioning.
The comparison with an active control group, that is
specifically designed to control for the non-specific ele-
ments of the MBI treatment and matched for duration
and format of group, will permit to assess with an ad-
equate methodology the role of mindfulness training on
changes in several psychosocial and physical measures.
The focus on depressive symptoms is supported from
what is stated by the Goldman Consensus Conference
[12] and by the American Academy of Neurology [13]
that highlight how depression is under-diagnosed and
under-treated in people with MS and can lead to a de-
crease in adherence to medication as well as a reduced
QoL. MBIs have been proven effective in improving de-
pressive symptoms and in enhancing QoL in many dif-
ferent chronic conditions and recently also in patients
with MS. MBIs can therefore be useful in counteracting
the suffering caused by the symptoms, the fatigue, the
depressive and anxiety symptomatology and the distress
in dealing with the disability.
Previous studies did not use objective measures of psy-
chosocial functioning of patients before and after the
intervention, and their findings were based only upon out-
come measures reported by patients. In this study we
propose to assess patients’ psychological functioning with
a semi-structured clinical interview (SCID) in addition to
the self-reported measures.
Furthermore, our project aims to involve patients’
caregivers. We expect that caregivers will benefit from
the treatment received, taking into consideration the
load of stress and difficulties related to the management
of a chronic disabling diseases like MS. In fact, a recent
study has shown that patients’ depressive state influ-
ences the deterioration of QoL and the depression of
caregivers [49].
Finally, our project is based on MBSR and MBCT pro-
tocols, but in order to maximize the clinical utility in
people suffering from MS and depression we tailored
mindfulness intervention on the needs of this specific
population [44]. We will apply a modified MBSR proto-
col integrated with body centered techniques from Sen-
sorimotor Psychotherapy [45]. SP was developed by Pat
Ogden on the model of Ron Kurtz, a body psychother-
apy built on mindfulness [50]. Most of these points are
already part of the MBSR and MBCT model, but in this
integration they are deepened more specifically to in-
crease clinical efficacy.
Results of this trial will provide methodologically
grounded data to consider the applicability of MBIs in
the usual practice of MS care centers and can help to
broad treatment possibilities for patients with MS-
related psychological distress.
This study has some potential limitations. The main
limitation of the project is the exclusion of patients with a
severe disability due to the characteristics of the interven-
tion, which requires a mobility at least partially preserved.
In addition, no neuroimaging and neurobiological assess-
ments are planned in the project.
Still and in conclusion, we deem that this study may
be the first clinical controlled trial in which MBI will be
investigated in comparison with an active control group
in patients with MS.
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